USask study finds post-surgical monoclonal antibody treatment reduces breast cancer recurrence

The team’s study, published Jan. 20 in Nature.com Scientific Reports, examined the medical records of all Saskatchewan women diagnosed with a small HER2-positive breast cancer between January 2008 and December 2017. Among the most aggressive of breast cancers, HER2 is named for the protein human epidermal growth factor receptor 2 that malfunctions to cause rapid cancer cell growth.

“HER2-positive breast cancer has been associated with high risk of recurrence,” said Ahmed, a professor and division head of oncology at USask’s College of Medicine.

A 12-month course of treatment with trastuzumab in conjunction with chemotherapy after surgery is the standard treatment for early-stage HER2-positive breast cancer tumours larger than a centimetre or have spread to lymph nodes, Ahmed said.

However, the benefit was not well-known of adjuvant (post-operative) trastuzumab treatment for smaller HER2-positive tumours that haven’t spread beyond the initial site (metastasized) to lymph nodes.

Using the health records, Ahmed’s team identified 91 women who had early-stage, non-metastasized HER2-positive breast cancers smaller than 10 millimetres. Overall, 39 patients whose tumours mostly were larger than 5mm had received adjuvant trastuzumab and chemotherapy, while 52 with smaller tumours had not received post-operative trastuzumab.

While the sample size is small, the study is population-based with no selection bias and covers a 10-year period, Ahmed said.

“Our study showed that women with HER2 positive tumours less than one centimetre and were node-negative had a low rate of recurrence,” Ahmed said. “However, those who received adjuvant trastuzumab had a further reduction in the risk recurrence. For example, women who did not receive adjuvant trastuzumab had a four-fold greater risk of recurrence.”

Overall, 97 per cent of women in the trastuzumab group were free of a breast cancer recurrence after 10 years, compared to 88 per cent among those who didn’t receive the treatment.

The analysis of this retrospective cohort study was statistically adjusted to account for such factors as patient ages and other risks, to make the findings as close as possible to those of a randomized study, Ahmed said.

He anticipates the findings of the study, which favour adjuvant trastuzumab for small tumours, will lead to its more frequent use to reduce the risk of cancer recurrence in younger women with tumours larger than 5mm.

However, since treatment toxicity is an important consideration in contemplating the use of adjuvant trastuzumab, a key point to examine is whether the duration of treatment should be shortened to six months from the current 12 months, he said.

-30-

For more information, contact: 

Victoria Dinh
USask Media Relations
306-966-5487
victoria.dinh@usask.ca